Clinical Ink, a global clinical trial technology company, has announced a wide-ranging Study Assurance Program to minimize financial impact of the disruption from COVID-19 on new and existing clinical trials. Because of the effect of global quarantines has dramatically impacted new patient recruitment and has substantially changed how existing patients participate in ongoing clinical trials, the Program addresses change order waivers, fees related to BYOD ePRO project management waived, as well as additional provisions.
For more information, click
